
样式: 排序: IF: - GO 导出 标记为已读
-
Sexual health outcomes after colorectal cancer diagnosis in females: a population-based cohort study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-06-01
Niki Oveisi, Eric C Sayre, Lori A Brotto, Vicki Cheng, Vienna Cheng, Sharlene Gill, Gillian E Hanley, Helen McTaggart-Cowan, Stuart Peacock, Meera Rayar, Amirrtha Srikanthan, Dani Taylor, Mikaela Barnes, Mary A De VeraBackground Colorectal cancer (CRC) affects a growing number of females. Our objective was to evaluate the impact of CRC on sexual health outcomes among females, while controlling for age. Methods We conducted a cohort study using administrative health data from the province of British Columbia (BC) including linked health visits and cancer registry from 1985–2017. The cohort included females with CRC
-
Risk of atherosclerotic cardiovascular disease after cancer diagnosis: findings from three prospective cohort studies J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-30
Qiang Liu, Qiaoli Wang, Kai Wang, Han Han, Molin Wang, Jing Wang, Mingyang Song, Edward GiovannucciBackground To determine the association between cancer diagnosis and subsequent risk of ASCVD, and to examine the trajectory of the association over time after cancer diagnosis. Methods We prospectively followed 108,689 women in the Nurses’ Health Study (NHS) (1984-2020), 113,569 women in the NHSII (1991-2019), and 45,328 men in the Health Professionals Follow-up Study (HPFS) (1986-2016) who were free
-
Response to Siegel, Kratzer, Smith et al. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-29
Archie Bleyer,Lynn A G Ries,Danielle B Cameron,Sara A Mansfield,Stuart E Siegel,Ronald D Barr -
Rising incidence of early-onset colorectal cancer: impact of anatomy and histology. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-29
Sara K Char,Jennifer A Chan,Kimmie Ng -
Risk of aggressive prostate cancer with successive generations in the U.S. among Latino men J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-27
Fei Chen, Adelynn Paik, Xin Sheng, Iona Cheng, Salma Shariff-Marco, Lynne R Wilkens, Loïc Le Marchand, David V Conti, Christopher A Haiman, Veronica Wendy SetiawanBackground US-born Latino men have a higher incidence of prostate cancer (PCa) than foreign-born Latino men. It was not clear whether these increases were exclusively due to increased detection of PCa in the US, changes in risk factors of PCa, or a combination of both. Methods In the Multiethnic Cohort (MEC) we evaluated the association between generational status and risk of PCa in 19,597 Latino men
-
Assisted reproductive technology utilization for cancer survivors: how we can do better. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-25
Erin Hupy,Zaraq Khan,Alessandra J Ainsworth,Chandra C Paff Shenoy -
Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource stratified guidelines J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-23
Brooke E Wilson, Kristin Wright, Manju Sengar, Richard Sullivan, Sallie-Anne Pearson, Michael B Barton, Bishal Gyawali, Elisabeth De Vries, Lorenzo Moja, C S Pramesh, Christopher M BoothBackground The Essential Medicines List (EML) and Resource Stratified Guidelines (RSG) both prioritize high-value medicines. We compare the 2023 EML cancer medicines list to global cancer statistics, examine the proportion of EML therapies recommended by RSGs, and identify gaps that merit evaluation by the EML Committee. Methods We compared the 2023 EML medicines for adult cancers with cancer incidence
-
Leisure-time physical activity after diagnosis and survival by cancer type: a pooled analysis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-21
Erika Rees-Punia, Lauren R Teras, Christina C Newton, Steven C Moore, I-Min Lee, Lauren Bates-Fraser, Den E Bloodworth, A Heather Eliassen, Lorelei Mucci, Brigid M Lynch, Meir Stampfer, Mingyang Song, Kristen D Brantley, Konrad H Stopsack, Charles E Matthews, Alpa V PatelPurpose Evidence for potential mortality benefits of leisure-time moderate-to-vigorous intensity physical activity (MVPA) for survivors of cancer types beyond breast and colorectal is limited. The aim of this study was to evaluate relationships between postdiagnosis MVPA and all-cause mortality in participants with a history of eleven cancer types. Methods Data were pooled from six United States-based
-
The impacts of the Dobbs ruling on US cancer care delivery J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-20
Margaret Katana Ogongo, Nicole Huberfeld, Karen Basen Engquist, Julie R Gralow, Farhad Islami, Beth Y Karlan, K Robin YabroffThe US Supreme Court’s ruling on Dobbs v Jackson Women’s Health Organization (Dobbs) in 2022 eliminated federal constitutional protection for abortion access. Dobbs has clinical and practical implications throughout the cancer control continuum. In abortion access-restrictive states, providers and patients with cancer who are pregnant will need to consider less efficacious cancer treatments, criminal
-
Lineages and sublineages of high-risk HPV types associated with cervical cancer and precancer: a systematic review and meta-analysis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-16
Eef Van Den Borst, Margo Bell, Ken Op De Beeck, Guy Van Camp, Severien Van Keer, Alex VorstersBACKGROUND Infection with high-risk types of the human papillomavirus (hrHPV) is known to cause cervical cancer. Cervical cancer risk varies greatly by genotype, which is therefore used in screening algorithms. A significant amount of research has also focused on the differential pathogenicity of hrHPV subtypes called lineages and sublineages (resp. 1.0-10% and 0.5-1.0% genetic difference), albeit
-
Unraveling the role of stromal disruption in aggressive breast cancer etiology and outcomes J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-14
Mustapha Abubakar, Máire A Duggan, Shaoqi Fan, Ruth M Pfeiffer, Scott Lawrence, Karun Mutreja, Alyssa Klein, Hela Koka, Thomas U Ahearn, Jill E Henry, Brian L Sprague, Pamela M Vacek, Donald L Weaver, Kathryn Richert-Boe, Teresa M Kimes, Nicolas Titiloye, Lawrence Edusei, Jonine D Figueroa, Xiaohong R Yang, Montserrat Garcia-Closas, Thomas E Rohan, Gretchen L GierachBackground Aggressive (typically high-grade) breast cancers (BCs) remain major contributors to BC-related mortality globally. The tissue changes underpinning their etiology and outcomes, however, remain poorly characterized. Methods Spatially resolved machine-learning algorithms were used to characterize “stromal disruption” as a morphological metric of reduced/altered extracellular matrix and increased
-
Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Active Lifestyle Study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-10
Jeannette M Schenk, Roman Gulati, Sarah J Beatty, Steven Plymate, Daniel W Lin, Atreya Dash, Michael P Porter, Matt Vandoren, Jonathan L Wright, Marian L NeuhouserAdiposity reduction has both cancer-specific and overall health benefits for patients with overweight or obesity. However, the indiscriminate loss of lean mass accompanying weight loss remains a concern for older cancer patients. Body composition was evaluated in the Prostate Active Lifestyle Study, a randomized controlled weight loss trial targeting caloric restriction and increased physical activity
-
Prostate cancer clinicopathological presentation in South-East Africa during the 2010 decade. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-09
Sean M Patrick,Winstar Mokua Ombuki,Joan Ndambuki,Micah O Oyaro,Meshack Bida,Pamela X Y Soh,Gail S Prins,,Vanessa M Hayes,M S Riana Bornman,Peter Mungai NgugiProstate cancer (PCa) is the leading cause of cancer-associated death amongst men across Sub-Saharan Africa, with Southern and East Africa ranking 1st and 5th globally. However, lack of coordinated National cancer registries has biased data towards single sourced, averaged or model estimates. Here, our retrospective study included 8,634 South-East African cases diagnosed between 2010-to-2019, which
-
Disaggregating cancer risk among Asian American and Pacific Islander solid organ transplant recipients. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-07
Stephanie Wang,Khushi Kohli,Isaac G Alty,Edward Christopher Dee -
Response to Li, Liu, Duan et al. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-07
Per Karlsson,Fyles Anthony,Bradley Arrick,Erik Holmberg,Martin Sjöström,David A Cameron,Linda J Williams,Ian Kunkler,Corey W Speers,Lori J Pierce,John P Bennett,Karen J Taylor -
Landscape assessment of patient-reported outcome item coverage of tyrosine kinase inhibitor-associated AEs J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-05
Emily L Paton, Jeremy P Cetnar, Janet Freeman-Daily, Jill Feldman, Bellinda L King-KallimanisBackground Patient-reported outcomes (PROs) are critical for assessing symptomatic adverse events (AEs) in non-small-cell lung cancer (NSCLC) clinical trials. However, PROs may not fully capture tyrosine kinase inhibitor (TKI)-specific AEs in metastatic NSCLC patients. This study evaluated coverage of TKI-related symptomatic AEs by commonly used PRO item libraries. Methods We compiled a list of FDA-approved
-
Post-diagnosis dietary and lifestyle factors and mortality outcomes among colorectal cancer patients: a meta-analysis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-05-03
Qiao-Yi Chen, Nana Keum, Edward L GiovannucciBackground While dietary and lifestyle factors are well-studied for colorectal cancer (CRC) prevention, less evidence exists on their impact on CRC survival. Methods PubMed and Embase were searched from inception to September 2024. Summary relative risk (SRR) and 95% confidence interval (CI) were estimated using the DerSimonian-Laird random-effects model. Results Lower all-cause mortality was observed
-
The prevalence of parental cancer history and in vitro fertilization utilization J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-30
Abby L Chen, Shufeng Li, Valerie L Baker, Philip J Lupo, Hazel B Nichols, Michael L Eisenberg, Barbara LukeBackground Advances in cancer treatment have led to an increased number of survivors who may subsequently have children. We aim to describe the prevalence of a parental cancer history with and without the utilization of in vitro fertilization (IVF) in several states in the United States. Methods This study used data from IVF cycles resulting in live births reported to the Society for Assisted Reproductive
-
Small steps, big impact: redefining cancer survival through lifestyle. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-29
Andrea Romanos-Nanclares,Edward L Giovannucci,A Heather Eliassen -
Racial and ethnic differences in HPV-related cancer incidence in the United States, 2001-2020 J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-28
Adino Tesfahun Tsegaye, Jaimie Z Shing, Jacqueline B Vo, Aimée R Kreimer, Meredith S ShielsBackground Human papillomavirus (HPV) causes cervical cancer and a proportion of oropharyngeal, vulvar, vaginal, penile, and anal cancers. Evaluating racial and ethnic heterogeneity by anatomic site will identify populations with the highest cancer incidence rates (IRs) and help to optimize available prevention strategies. Methods Using the 2001-2020 US Cancer Statistics database, we estimated age-standardized
-
Father’s occupation and colorectal cancer in his adult offspring J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-24
Caitlin C Murphy, Emanuelle M Dias, Piera M Cirillo, Nickilou Y Krigbaum, Barbara A CohnBackground Growing evidence suggests transmission of colorectal cancer risk through the maternal line. There is scant information about transmission through the paternal line, despite plausible evidence from mammal experiments. Methods We examined the association between paternal occupation and colorectal cancer in the Child Health and Development Studies, a multi-generational cohort followed for 60
-
Outcomes after solid organ transplantation in survivors of childhood, adolescent and young adult cancer: A population-based study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-23
Paul C Nathan, Cindy Lau, Vicky L Ng, Mar Miserachs, Chia Wei Teoh, Melinda Solomon, Anne I Dipchand, Maria Locke, Sumit GuptaBackground Cancer treatment can lead to organ toxicity requiring solid organ transplant (SOT). Transplant teams must evaluate the appropriateness of SOT in survivors of childhood, or adolescent/young adult (AYA) cancer. Methods Children treated at a provincial (Ontario, Canada) pediatric center for any cancer between 1986-2021, and AYA (15-21 years) treated in an adult center for four common cancer
-
Historical redlining and mortality in children, adolescents, and young adults with cancer in California, 2000-2019 J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-22
Kristine A Karvonen, Annie Vu, Katherine Lin, Joseph Gibbons, Jason A Mendoza, Eric J Chow, Lena E Winestone, Scarlett L GomezBackground Historical redlining, or the Home Owners Loan Corporation (HOLC) program’s racially biased mortgage risk monitoring maps in the 1930s, is implicated in shaping modern neighborhoods and health outcomes. This retrospective cohort study evaluates the association between redlining and mortality in young cancer patients. Methods Using the California Cancer Registry, we identified patients <25
-
Mammographic classification of interval breast cancers and artificial intelligence performance J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-17
Tiffany T Yu, Anne C Hoyt, Melissa M Joines, Cheryce P Fischer, Nazanin Yaghmai, James S Chalfant, Lucy Chow, Shabnam Mortazavi, Christopher D Sears, James Sayre, Joann G Elmore, William Hsu, Hannah S MilchBackground European studies suggest artificial intelligence (AI) can reduce interval breast cancers (IBCs). However, research on IBC classification and AI’s effectiveness in the U.S., particularly using digital breast tomosynthesis (DBT) and annual screening, is limited. We aimed to mammographically classify IBCs and assess AI performance using a 12-month screening interval. Methods From digital mammography
-
Treatment deescalation for older women with favorable breast cancers: patient values and shared decision making. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-15
Deborah R Smith,Silvia C Formenti -
Secondary malignancies after treatment of testicular germ cell tumors: a systematic review & meta-analysis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-13
Ahmad Mousa, Ali Amiri, Sanchit Kaushal, Emma Wilson, Viranda Jayalath, David-Dan Nguyen, Isabelle Tan, Robert J HamiltonBackground Testicular germ cell tumours (TGCTs) are the most common malignancy in men 15-35 years of age. Management options for men with TGCTs include surgery, radiation and/or chemotherapy. Given TGCTs’ excellent survival, most patients live long enough to experience delayed treatment toxicities, warranting careful consideration of therapeutic decisions. An important outcome of interest is the development
-
Ten years of robot-assisted versus laparoscopic total mesorectal excision for rectal cancer (short-term RESOLUTION) J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-13
Rauand Duhoky, Ritch T J Geitenbeek, Guglielmo Niccolò Piozzi, Thijs A Burghgraef, Christina A Fleming, Shamsul Masum, Adrian Hopgood, Timothy Rockall, Quentin Denost, Christophe Taoum, Roel Hompes, Jim Briggs, Esther C J Consten, Jim S KhanBackground Total mesorectal excision is the gold standard for rectal cancer surgery, with laparoscopic and robot-assisted approaches commonly employed. While robot-assisted surgery may offer technical advantages, there is limited evidence comparing short-term outcomes of laparoscopic and robot-assisted techniques, particularly in Western European populations. This study aimed to assess the short-term
-
A working group report from the 2024 NCI/GCSC endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-11
Casey M Cosgrove, Dmitriy Zamarin, Jose R Conejo-Garcia, Kari E Hacker, Roberto Vargas, Panagiotis A Konstantinopoulos, Haider S Mahdi, Stephanie Gaillard, Stephanie Markovina, Elise C Kohn, Sarah F AdamsEndometrial cancer (EC) is now the leading cause of gynecologic cancer death in the United States. Recognizing the urgent need to improve outcomes for patients diagnosed with EC, The National Cancer Institute (NCI) Gynecologic Cancer Steering Committee (GCSC) convened a Clinical Trials Planning Meeting (CTPM) on January 8th and 9th 2024, “Refining the Approach to Endometrial Cancer in the Immunotherapy
-
Neoadjuvant versus perioperative chemo-immunotherapy according to pathological response in resectable NSCLC: a reconstructed individual patient data meta-analysis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-11
Antonio Nuccio, Fabio Salomone, Alberto Servetto, Biagio Ricciuti, Daniele Marinelli, Alessandra Bulotta, Giulia Veronesi, Marina Chiara Garassino, Valter Torri, Benjamin Besse, Giuseppe Viscardi, Roberto FerraraNeoadjuvant chemo-immunotherapy transformed early-stage non-small cell lung cancer (NSCLC) treatment. However, the prognostic value of different pathological responses and the impact of adjuvant immunotherapy within a chemo-immunotherapy perioperative strategy remains unclear. We estimated time-to-event outcomes by graphical reconstruction of event-free survival (EFS) curves by pathological response
-
Effect size estimation in cooperative group and industry sponsored phase 3 oncology trials J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-08
Sonal S Noticewala, Adam Grippin, Ramez Kouzy, Joseph Abi Jaoude, Avital Miller, Alexander Sherry, Ethan B LudmirOverly optimistic estimations of effect sizes may lead to underpowered studies and risk of erroneously dismissing effective treatments. To understand the prevalence and factors contributing to estimation of effect sizes, we evaluated 385 superiority-design phase 3 oncology randomized controlled trials (RCTs) with pre-specified and observed hazard ratios (HR) in published manuscripts. Of these, 88%
-
Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-08
Sheng Nie, Lisha Cao, Licong Su, Shiyu Zhou, Yanqin Li, Ruixuan Chen, Fan Luo, Qi Gao, Yuxin Lin, Zhixin Guo, Xin Xu, Guobao WangBackground The survival benefits of prophylactic antiviral therapy for cancer patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who require immunosuppressive therapy (IST) remain unclear. The present study aims to evaluate the association of prophylactic antiviral therapy with all-cause and cause-specific mortality in cancer patients. Methods This multicenter, retrospective cohort
-
Following the American Cancer Society guideline for cancer survivors and obesity-related cancer survival. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-03
Ying Wang,Christina C Newton,Marjorie L McCullough,Lauren R Teras,Clara Bodelon,Erika Rees-Punia,Caroline Y Um,Laura Makaroff,Alpa V PatelBACKGROUND In 2022, the American Cancer Society updated its guideline for cancer survivors. However, the impact of post-diagnosis adherence on mortality risk for those with obesity-related cancers remains unclear. METHODS This study followed nonsmoking participants from the Cancer Prevention Study-II Nutrition Cohort diagnosed with obesity-related cancers between 1992 and 2002 through 2020. Post-diagnosis
-
Antihypertensive drugs and survival outcomes in oropharyngeal squamous cell carcinoma patients J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-04-03
Che-Min Lee, Brennan J Wadsworth, Ryan Urban, Meredith A Clark, Rocky Shi, Daegan Sit, Sarah N Hamilton, Kevin L BennewithBackground Radiation therapy is commonly used to treat head and neck cancer patients, and response may be improved by combining radiation with preexisting medications. Based on recent preclinical and retrospective patient data, we hypothesized that antihypertensive drugs may improve radiotherapy outcomes. Methods Retrospective analyses were conducted on 1077 oropharyngeal squamous cell carcinoma and
-
A randomized study of 2 risk assessment models for individualized breast cancer risk estimation J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-31
Adrià López-Fernández, Laura Duran-Lozano, Guillermo Villacampa, Mónica Pardo, Eduard Pérez, Esther Darder, Anna Vallmajó, Rosa Alfonso, Mara Cruellas, Ariadna Roqué, Mireia Cartró, Adriana Bareas, Estela Carrasco, Alejandra Rezqallah, Ana Raquel Jimenez-Macedo, Sara Torres-Esquius, Maite Torres, Consol Lopez, Martín Espinosa, Alex Teulé, Elisabet Munté, Noemi Tuset, Orland Diez, Lidia FeliubadalóBackground Estimating breast cancer risk involves quantifying genetic and non-genetic factors. This supports health interventions and risk communication to ensure adherence to screening recommendations. This study evaluated the change in risk estimation when incorporating breast density and polygenic risk score (PRS) into the baseline cancer risk assessment and compared the efficacy of two risk-assessment
-
Extended endocrine therapy use and decision making after breast cancer diagnosis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-31
Allison W Kurian, Allison K C Furgal, Archana Radhakrishnan, Christine M Veenstra, Paul Abrahamse, Kevin C Ward, Ann S Hamilton, Timothy P Hofer, Steven J Katz, Lauren P Wallner, Sarah T HawleyPurpose Adjuvant endocrine therapy is recommended to extend beyond five years for stage II breast cancer, with less consensus for extension in stage I. We aimed to understand use of and decision-making about extended endocrine therapy. Patients and Methods Women aged 20-79 diagnosed with stage I-II breast cancer in 2014-15 and reported to Georgia and Los Angeles County SEER registries were surveyed
-
Development of a Multi-Institutional Dataset to Validate a Novel Inflammatory Breast Cancer Diagnostic Score J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-31
Filipa Lynce, Samuel M Niman, Megumi Kai, Sean Ryan Ma, Elizabeth Troll, Li Li, Kathy D Miller, Reshma Jagsi, Ginny Mason, Beth A Overmoyer, H T Carisa Le-Petross, Faina Nakhlis, Savitri Krishnamurthy, Beth T Harrison, Susie X Sun, Eren D Yeh, Jennifer R Bellon, Laura E Warren, Michael C Stauder, Meredith M Regan, Wendy A WoodwardPurpose Susan G. Komen, the Inflammatory Breast Cancer (IBC) Research Foundation, and the Milburn Foundation convened patient advocates, clinicians, and researchers to propose novel quantitative scoring rubrics for IBC diagnosis. In this study, we developed a multi-institutional clinical dataset to test and validate the proposed scoring system. Methods IBC (N = 988) and non-IBC (N = 332) cases were
-
Comparing waist circumference with body mass index on obesity-related cancer risk: a pooled Swedish study J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-31
Ming Sun, Christel Häggström, Marisa Da Silva, Innocent B Mboya, Ylva Trolle Lagerros, Karl Michaëlsson, Sven Sandin, Jerzy Leppert, Sara Hägg, Sölve Elmståhl, Patrik K E Magnusson, Stefan Söderberg, Weiyao Yin, Abbas Chabok, Angela Wood, Tanja Stocks, Josef FritzBackground General adiposity, assessed by body mass index (BMI), is a well-established cancer risk factor. This study compared waist circumference (WC), a measure of abdominal adiposity, with BMI as a risk factor for obesity-related cancers, and assessed whether WC provides additional information beyond BMI. Methods We analyzed data from 339 190 individuals in a pooled Swedish cohort with baseline
-
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-31
Katie A Greenzang, Kathleen E Montgomery, Adam DuVall, Michael E Roth, Mark Krailo, Michelle M Nuño, Lindsay Renfro, Natalie DelRocco, John Doski, Kara Kelly, Sharon M Castellino, Jennifer McNeer, Maureen M O’Brien, Damon Reed, Katherine Janeway, Pamela S Hinds, Sue Zupanec, Susan K ParsonsUnderstanding the patient experience of treatment toxicities and their impact on health-related quality of life (HRQoL) of cancer treatments requires asking patients themselves using patient-reported outcomes (PROs). Over the past twenty years, the National Institutes of Health (NIH) sponsored several tools, namely Patient-Reported Outcome Measurement Information System (PROMIS) measures and the Patient-Reported
-
Prevalence by therapy line and incidence of breast cancer brain metastases in 18,075 patients J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-31
Sarah L Sammons, Thibaut Sanglier, Jose Pablo Leone, Timothy K Erick, Peter Lambert, Filippo Montemurro, Raf Poppe, Eleonora Restuccia, Sara M Tolaney, Nancy U LinImportance Brain metastases portend poor prognosis in patients with metastatic breast cancer (MBC). Designing treatment and prevention clinical trials requires knowledge of brain metastases incidence with each line of therapy. Objectives We assessed the prevalence and cumulative incidence of brain metastases in a large MBC patient cohort by subtype and line of therapy, and the impact of HER2-low expression
-
In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-29
Philip C Mack, James M Crawford, Andres Chang, Anna Yin, Sabra L Klein, Patrick Shea, Fred R Hirsch, David Zidar, Viviana Simon, Charles Gleason, Russell McBride, Carlos Cordon-Cardo, Jennifer VanOudenhove, Stephanie Halene, F Eun-Hyung Lee, Nicholas Mantis, Lawrence H Kushi, Daniela Weiskopf, Akil Merchant, Karen L Reckamp, Jacek Skarbinski, Jane C FigueiredoThe COVID-19 pandemic created the urgent need to monitor risk of SARS-CoV-2 infection and mortality, and to evaluate immune responses to novel vaccines. A foremost concern was the unknown risks to patients with cancer, considering their overall health, immune status and interactions with cancer therapies. The U.S. National Cancer Institute, in partnership with the National Institute of Allergy and
-
Response to Zhou, Cui, Sun et al. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-27
Stephanie Tuminello,Wiley M Turner,Emanuela Taioli -
Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study). J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-25
Liang Xia,Qiang Pu,Ran Kang,Jiandong Mei,Lu Li,Ying Yang,Senyi Deng,Gang Feng,Yulan Deng,Fanyi Gan,Yidan Lin,Lin Ma,Feng Lin,Yong Yuan,Yang Hu,Chenglin Guo,Hu Liao,Chengwu Liu,Yunke Zhu,Wenping Wang,Zheng Liu,Yuyang Xu,Kaidi Li,Chuan Li,Weizhi Chen,Qingyun Li,Bo Du,Xiaolong Zhang,Yingli Kou,Yun Wang,Zhu Wu,Guowei Che,Yaohui Chen,Shensi Shen,Longqi Chen,Dan Xie,Lunxu LiuBACKGROUND Circulating tumor DNA (ctDNA) is valuable for detecting minimal residual disease (MRD). However, studies involving long-term blood sampling are required to comprehensively interpret the clinical use of ctDNA analyses. METHODS We conducted a prospective multicenter cohort study (LUNGCA) for dynamic ctDNA monitoring in lung cancer patients receiving curative-intent surgery. ctDNA analysis
-
Sex-specific radiation-associated lung cancer mortality risks as impacted by smoking among US radiologic technologists J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-22
Cato M Milder, Elizabeth K Cahoon, Sara J Schonfeld, Dale L Preston, Bruce H Alexander, Martha S Linet, Cari M KitaharaBackground The Life Span Study of Japanese atomic bomb survivors estimated greater risks of radiation-associated lung cancer among females than males, with direct implications for occupational radiation safety policy. To evaluate replicability of these findings in radiation workers, we assessed sex-specific radiation-associated risks of lung cancer mortality in a large cohort of U.S. radiologic technologists
-
Effects of exercise on inflammation in female survivors of nonmetastatic breast cancer: a systematic review and meta-analysis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-22
Francesco Bettariga, Dennis R Taaffe, Anita Borsati, Alice Avancini, Sara Pilotto, Stefano G Lazzarini, Pedro Lopez, Luca Maestroni, Umberto Crainich, John P Campbell, Timothy D Clay, Daniel A Galvão, Robert U NewtonBackground Despite advances in breast cancer treatment, recurrence remains common and contributes to higher mortality risk. Among the potential mechanisms, inflammation plays a key role in recurrence by promoting tumor progression. Exercise provides a wide array of health benefits and may reduce inflammation, potentially reducing mortality risk. However, the effects of exercise, including mode (ie
-
Associations of self-identified race and ethnicity and genetic ancestry with mortality among cancer survivors J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-22
Jacqueline B Vo, Derek W Brown, Ian D Buller, Jaimie Z Shing, Naoise Synnott, Rena R Jones, Maria Teresa Landi, Wen-Yi Huang, Mitchell J Machiela, Amy Berrington De Gonzalez, Timiya S Nolan, Peter Kraft, Faustine Williams, Neal D FreedmanSelf-identified race and ethnicity (SIRE) and genetic ancestry (GA) are potentially associated with disparities in health outcomes; however, independent effects of SIRE and GA on mortality in cancer survivors including when adjusting for multiple risk factors are understudied. Among 23,445 cancer survivors in the Prostate, Lung, Colorectal, and Ovarian Screening Trial, SIRE was associated with mortality
-
Spectrum of cancer risk in Asian American and Pacific Islander solid organ transplant recipients J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-22
Jun Tao, Jaimie Z Shing, Kelly Yu, Aimée R Kreimer, Mei-Chin Hsieh, Karen S Pawlish, Jie Li, Baozhen Qiao, Judy R Rees, Kekoa Taparra, Jacqueline B Vo, Eric A EngelsBackground Solid organ transplant recipients (SOTRs) have increased cancer risk, which may differ across racial groups. Cancer risk among Asian American and Pacific Islander SOTRs is ill-defined. Methods We evaluated Asian, Pacific Islander, and White SOTRs from a linkage of the United States SOTR registry with 34 cancer registries (1990-2019). We calculated age-and-sex adjusted incidence rate ratios
-
The NuRD-SWI/SNF antagonism regulates the coordinated activation of EMT and inflammation in oral cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-22
Roberto Stabile, Francesco A Tucci, Mathijs P Verhagen, Carmen Embregts, Thierry P P van den Bosch, Rosalie Joosten, Maria J De Herdt, Berdine van der Steen, Alex L Nigg, Senada Koljenović, Jose A Hardillo, C Peter Verrijzer, Adrian Biddle, Robert J Baatenburg de Jong, Pieter J M Leenen, Riccardo FoddePhenotypic plasticity and inflammation, two well-established hallmarks of cancer, play key roles in local invasion and distant metastasis by enabling the rapid adaptation of tumor cells to dynamic micro-environmental changes. Here, we show that in oral squamous carcinoma cell carcinoma (OSCC), the competition between the NuRD and SWI/SNF chromatin remodeling complexes plays a pivotal role in regulating
-
Association of opioid and benzodiazepine coprescribing with adverse events among older adults with cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-21
Devon K Check, Samir Soneji, Harvey Jay Cohen, Andrea Des Marais, Katie F Jones, Charles E Gaber, Jessica S Merlin, Amy O’Regan, Nicole Fergestrom, Lauren E Wilson, Aaron N WinnBackground Many older adults with cancer are coprescribed opioids/benzodiazepines; evidence on harms is lacking. Methods Using SEER-Medicare (2012-2019), we identified patients with breast, colorectal, or lung cancer. Cox proportional hazards models estimated the adjusted hazard ratios (HR) of coprescribing (measured from claims, at the day level) with the immediate risk of overdose, fall/fracture
-
The Role of Regional and Practice Trial Sites in Non-Representative Randomized Cancer Trial Enrollment J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-20
Sachin J Shah, Christopher R Manz, Brendan Balthis, Hari S Raman, Jason Abaluck, Nancy L Keating, Leila AghaRepresentative trials are critical to advancing cancer treatment, yet little is known about how geographic siting contributes to non-representative enrollment. Using patient-level data, we determined how the choice of trial-enrolling regions and practices impacts representativeness. We created a SEER-Medicare cohort of people ≥65 years old with lung, breast, pancreatic, or renal cancer (2014-2019)
-
Utilizing Patient Input in Rectal Cancer Trial Design J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-20
Janet Alvarez, Wini Zambare, Manju George, Reese Garcia, Phuong Gallagher, Caleah Kitchens, Aron Bercz, Min Jung Kim, Paul B Romesser, Andrea Cercek, Julio Garcia-Aguilar, Hanna Sanoff, Thomas J George, Theodore S Hong, Greg Yothers, Philip A Philip, Tareq Al Baghdadi, Olatunji B Alese, Ardaman Shergill, Eileen M O’Reilly, Jeffrey A Meyerhardt, Natally Horvat, Arvind Dasari, William A Hall, Qian ShiBackground The treatment of locally advanced rectal cancer now includes “watch-and-wait” (WW) management for patients who exhibit a clinical complete response (cCR) to total neoadjuvant therapy (TNT). We assessed patients’ knowledge and preferences regarding WW with the goal of incorporating patient input into clinical trial design. Methods Rectal cancer patients in advocacy groups (COLONTOWN/Rectalburgh
-
Initial evaluation of a new cervical screening strategy combining human papillomavirus genotyping and automated visual evaluation: the Human Papillomavirus-Automated Visual Evaluation Consortium. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-18
Brian Befano,Jayashree Kalpathy-Cramer,Didem Egemen,Federica Inturrisi,José Jeronimo,Ana Cecilia Rodríguez,Nicole Campos,Miriam Cremer,Ana Ribeiro,Kayode Olusegun Ajenifuja,Andrew Goldstein,Amna Haider,Karen Yeates,Margaret Madeleine,Teresa Norris,Jaqueline Figueroa,Karla Alfaro,Tainá Raiol,Clement Adepiti,Judith Norman,George Kassim Chilinda,Bariki Mchome,Yeycy Donastorg,Xolisili Dlamini,Gabriel ConzueloThe HPV-Automated Visual Evaluation (PAVE) Consortium is validating a cervical screening strategy enabling accurate cervical screening in resource-limited settings. A rapid, low-cost HPV assay permits sensitive HPV testing of self-collected vaginal specimens; HPV-negative women are reassured. Triage of positives combines HPV genotyping (four groups in order of cancer risk) and visual inspection assisted
-
Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-12
Yuhan Huang, Marilyn L Kwan, Susan R Heckbert, Nicholas L Smith, Megan Othus, Cecile A Laurent, Janise M Roh, Eileen Rillamas-Sun, Valerie S Lee, Tatjana Kolevska, Richard K Cheng, Carlos Irribarren, Mai Nguyen-Huynh, Dawn L Hershman, Lawrence H Kushi, Heather GreenleeBackground There are increasing concerns of cardiovascular safety related to endocrine therapy use in women with breast cancer (BC). We examined risk of cardiovascular disease (CVD) events and mortality associated with endocrine therapy use in postmenopausal women with early-stage BC. Methods Postmenopausal women diagnosed with stage I-III hormone receptor-positive BC from 2005 to 2013 were included
-
Comparative effectiveness of various nonpharmacological interventions, including traditional Chinese medicine-based interventions for cancer-related cognitive impairment: a comprehensive network meta-analysis J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-12
Mu-Hsing Ho, Lizhen Wang, Justin Wei Ho Wong, Gongkai Xin, Qianyi Zhang, Yen-Kuang Lin, Denise Shuk Ting Cheung, Janette L Vardy, Chia-Chin LinBackground Cancer-related cognitive impairment is a common complication of cancer and its treatment. The effectiveness of Traditional Chinese Medicine (TCM)-based interventions in improving subjective and objective cognitive function has not yet been investigated in previous network meta-analyses. This study aimed to evaluate the comparative effectiveness of nonpharmacological interventions including
-
Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-12
Malay K Sannigrahi, Lovely Raghav, Dominick J Rich, Travis P Schrank, Joseph A Califano, John N Lukens, Lova Sun, Iain M Morgan, Roger B Cohen, Alexander Lin, Xinyi Liu, Eric J Brown, Jianxin You, Lisa Mirabello, Sambit K Mishra, David Shimunov, Robert M Brody, Alexander T Pearson, Phyllis A Gimotty, Ahmed Diab, Jalal B Jalaly, Devraj BasuBackground Limited understanding of the biology predisposing certain human papillomavirus-related (HPV+) oropharyngeal squamous cell carcinomas (OPSCCs) to relapse impedes therapeutic personalization. We aimed to identify molecular traits that distinguish recurrence-prone tumors. Methods 50 HPV+ OPSCCs that later recurred (cases) and 50 non-recurrent controls matched for stage, therapy, and smoking
-
HPV vaccine impact: genotype-specific changes in cervical pre-cancer share similarities with changes in cervical screening cytology. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-11
Rachael Adcock,Cosette M Wheeler,William C Hunt,Norah E Torrez-Martinez,Michael Robertson,Ruth McDonald,Nancy E Joste,Mark H Stoler,Maurits N C de Koning,Wim G V Quint,BACKGROUND Following human papillomavirus (HPV) vaccine introduction, declines in the prevalence of HPV vaccine types have been observed in screening cytology, but data from the United States describing HPV type-specific changes in cervical intraepithelial neoplasia (CIN) grades 2-3 and adenocarcinoma in situ (CIN2/CIN3/AIS) are limited. METHODS A state-wide sample of individuals with cervical biopsies
-
Determinants of late metastases in renal cell carcinoma J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-11
Payal Kapur, Hua Zhong, Alana Christie, Haitao Xu, Qi Cai, Ellen Araj, David Kim, Jeffrey Miyata, Vanina T Tcheuyap, Colleen T Ball, David D Thiel, Alexander Parker, Samuel O Antwi, Brad C Leibovich, Zora Modrusan, John C Cheville, James BrugarolasThe mechanisms underlying metastatic latency in renal cell carcinoma (RCC) remain poorly understood. This study evaluated two large independent cohorts for differences in tumor biology between patients who developed metastases early (≤1 year after nephrectomy) and those with late-onset (>3 years). In the discovery cohort (n = 161), late-metastatic RCC (late-mRCC) was associated with clear cell histology
-
Facility exposure to wildfire disasters and hospital length of stay following lung cancer surgery J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-11
Leticia M Nogueira, K Robin Yabroff, Elizabeth Yates, James M Shultz, R Burciaga Valdez, Amruta Nori-SarmaBackground Wildfires pose substantial health and safety threats to patients recovering from lung cancer surgery. Without specific disaster preparedness guidelines, surgical oncologists might resort to improvisational strategies, such as extending post-operative length of stay (LOS) to support surgical recovery and better protect the health and safety of patients. Methods Individuals aged ≥18 years
-
Radiotherapy results in decreased time to second cancer in children with Li Fraumeni syndrome J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-10
Emma R Woodward, John-Paul Kilday, Stephanie Ng, Anna Kelsey, D Gareth R EvansLi Fraumeni Syndrome (LFS) arising from germline TP53 mutation results in defective DNA repair and increased risk of multiple primary cancers beginning in childhood. Curative intent radiotherapy is often used to treat childhood cancer but its impact in children in LFS has not been reviewed. We undertook a retrospective case-series review of 4 children with a solid cancer diagnosed ≤16years to assess
-
Trends in Young-Onset Cancer Incidence: A Modeling Perspective J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-05
Lukas Owens, Allison Fung, Jonathan Shuhendler, Joseph Glick, Marc D Ryser, Roman Gulati, Ruth EtzioniBackground Recent increases in the diagnosis of certain cancers among younger individuals are generating intense concern. Many studies attribute the increase in so-called “young-onset” cancer to an etiologic cause but questions have also arisen about the role of earlier diagnosis. Methods We simulate incidence trends from a natural history model that includes healthy, preclinical, and clinical disease
-
National trends in oncology specialists’ EHR inbox work, 2019–2022 J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2025-03-05
A Jay Holmgren, Nate C Apathy, Jennie Crews, Tait ShanafeltBackground Electronic health record (EHR) burden is an important driver of the ongoing physician burnout crisis. EHR-based messaging (also known as inbox) in particular, including messages from patients, is associated with burnout and decreased well-being. Little is known regarding EHR messaging burden for oncologists. To address this, we assessed trends in oncologist EHR messaging volume and EHR time